CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more
CanSino Biologics Inc - Asset Resilience Ratio
CanSino Biologics Inc (CASBF) has an Asset Resilience Ratio of 19.01% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how CanSino Biologics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down CanSino Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.39 Billion | 19.01% |
| Total Liquid Assets | $1.39 Billion | 19.01% |
Asset Resilience Insights
- Good Liquidity Position: CanSino Biologics Inc maintains a healthy 19.01% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
CanSino Biologics Inc Industry Peers by Asset Resilience Ratio
Compare CanSino Biologics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for CanSino Biologics Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for CanSino Biologics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.60% | $1.64 Billion | $7.96 Billion | -1.65pp |
| 2023-12-31 | 22.25% | $2.07 Billion | $9.32 Billion | -0.01pp |
| 2022-12-31 | 22.25% | $2.55 Billion | $11.47 Billion | +2.66pp |
| 2021-12-31 | 19.59% | $2.33 Billion | $11.87 Billion | +9.71pp |
| 2020-12-31 | 9.88% | $666.64 Million | $6.75 Billion | -21.07pp |
| 2019-12-31 | 30.95% | $552.34 Million | $1.78 Billion | +13.36pp |
| 2018-12-31 | 17.59% | $140.00 Million | $795.88 Million | -28.88pp |
| 2017-12-31 | 46.47% | $402.64 Million | $866.36 Million | +17.66pp |
| 2016-12-31 | 28.82% | $94.00 Million | $326.17 Million | -- |